🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are escalating around the world, with figures suggesting in excess of 82 million infections per year. Especially elevated rates are seen in Africa and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a record high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary advancement in the reality of increasing worldwide cases, escalating drug resistance and the very limited therapeutic options presently on offer.”

Health officials are particularly alarmed about the rise in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". A tracking program revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Secure Approval

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US FDA in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists anticipate that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the pharmaceutical company GSK, gained clearance in concurrent days. This drug, which is employed against UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This approval represents a significant shift in the management of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Results and Global Access

According to data released by a major medical journal, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which combines an injection and a pill. The research included over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the authority to license and sell the drug in many regions with limited resources.

Medical professionals on the front lines have shared optimism. Having a one-pill regimen such as this is seen as a "revolutionary step" for public health efforts. This is considered vital to lessen the impact of the infection for individuals and to stop the proliferation of extremely resistant gonorrhoea around the world.